Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.57 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 10/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850827 | 0.97 | SMYD2 (0.54) | SMYD2GPR52CACNA1GCYP2C9CYP2C19 | |
| SCHEMBL1851120 | 0.90 | GPR52 (0.53) | SMYD2GPR52CYP2C9CYP2C19DRD4 | |
| SCHEMBL1850828 | 0.83 | SIGMAR1 (0.44) | SMYD2GPR52DRD4 | |
| SCHEMBL1849693 | 0.81 | GPR52 (0.52) | GPR52 | |
| SCHEMBL1855327 | 0.80 | GPR52 (0.51) | GPR52DRD4MAPT | |
| SCHEMBL7959088 | 0.77 | TAS1R3 (0.53) | GPR52 | |
| SCHEMBL1850921 | 0.75 | GPR52 (0.49) | GPR52CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL3219252 | 0.75 | GPR52 (0.77) | GPR52 | |
| SCHEMBL1850964 | 0.75 | SMYD2 (0.49) | SMYD2GPR52CYP2C9CYP2C19DRD4 | |
| SCHEMBL3222089 | 0.74 | GPR52 (0.78) | GPR52MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | SMYD2 2916/4885GPR52 1/4885CACNA1G 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.